Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.48 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947672 | 1.00 | GPR119 (0.64) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6356496 | 0.95 | GPR119 (0.59) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3104760 | 0.86 | GPR119 (0.60) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30150192 | 0.86 | MAPT (0.56) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL594965 | 0.86 | MAPT (0.56) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL25187518 | 0.85 | GPR119 (0.59) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30893585 | 0.85 | GPR119 (0.59) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20423342 | 0.85 | GPR119 (0.50) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30672845 | 0.85 | GPR119 (0.50) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL25195794 | 0.84 | GPR119 (0.64) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-118201911-A | Compounds and their use as GPR183 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507474-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| WO-2010146083-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | GPR183, GPR180, GPR65 | GPR119 17/4885MAPT 3530/4885LMNA 3500/4885 |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | GPR119 3961/4885MAPT 2856/4885LMNA 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.